2011
Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial
Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial. Journal Of The American College Of Cardiology 2011, 57: 2389-2397. PMID: 21658558, DOI: 10.1016/j.jacc.2011.02.032.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, Balloon, CoronaryCardiac CatheterizationCoronary AngiographyCoronary Artery BypassElectrocardiographyEmergency TreatmentFemaleHeparin, Low-Molecular-WeightHirudinsHospital MortalityHumansItalyKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPeptide FragmentsPrognosisProportional Hazards ModelsProspective StudiesRecombinant ProteinsRisk AssessmentROC CurveSeverity of Illness IndexStatistics, NonparametricSurvival AnalysisTreatment OutcomeTriageConceptsSegment elevation acute coronary syndromesElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeSYNTAX scoreCoronary syndromeCardiac deathACUITY trialIndependent predictorsPredictive valueTarget vessel revascularization rateStable ischemic heart diseaseTriple-vessel coronary diseaseVessel revascularization rateCardiac mortality rateMyocardial infarction ratePre-specified subgroupsRisk-stratify patientsIschemic heart diseaseAngiographic substudySS tertilesInfarction rateRevascularization ratesCoronary interventionCoronary disease
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients